Tormentic acid
Based on 2 publication(s) in Google Scholar
Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties.
For research use only. We do not sell to patients.
- Purity: 98.38%
- CAS No.: 13850-16-3
- Formula: C30H48O5
- Molecular Weight:488.70
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Tormentic acid
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 518A2 | IC50 |
>30 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| 518A2 | IC50 |
>30 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| 8505C | IC50 |
23.4 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| 8505C | IC50 |
23.4 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A253 cell line | IC50 |
>30 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A253 cell line | IC50 |
>30 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A2780 | IC50 |
>30 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A2780 | IC50 |
>30 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A549 | IC50 |
31 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A549 | IC50 |
31 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| A549 | IC50 |
62.36 μg/mL
Compound: 2; TA
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 30108878] |
| Bel-7402 | IC50 |
54.22 μg/mL
Compound: 2; TA
|
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 30108878] |
| DLD-1 | IC50 |
31 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| DLD-1 | IC50 |
31 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| H9 | IC50 |
15 μg/mL
Compound: 9
|
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
|
[PMID: 9748372] |
| Hepatocyte | IC50 |
9.5 μM
Compound: 298
|
Hepatoprotective activity against D-GaIN-induced toxicity in mouse hepatocyte relative to control
Hepatoprotective activity against D-GaIN-induced toxicity in mouse hepatocyte relative to control
|
[PMID: 29353722] |
| HepG2 | IC50 |
40.57 μg/mL
Compound: 2; TA
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 30108878] |
| K562 | IC50 |
89.36 μM
Compound: 2
|
Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 17889544] |
| MCF7 | IC50 |
32.3 μM
Compound: 1, tormentic acid
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| MCF7 | IC50 |
32.3 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| MCF7 | IC50 |
24.23 μg/mL
Compound: 2; TA
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 30108878] |
| NIH3T3 | IC50 |
>30 μM
Compound: 1, tormentic acid
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| NIH3T3 | IC50 |
>30 μmol
Compound: 1, tormentic acid
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22995818] |
| RAW264.7 | IC50 |
24.9 μM
Compound: 14
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay
|
[PMID: 25245917] |
| SK-OV-3 | IC50 |
2.4 μM
Compound: 20
|
Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)
Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)
|
[PMID: 35500202] |
| SK-OV-3 | IC50 |
23.24 μM
Compound: 20
|
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 35500202] |
Tormentic acid inhibits LPS-induced iNOS, COX-2, and TNF-α expression through inactivation of the nuclear factor-κb pathway in RAW 264.7 macrophages[1].
Tormentic acid suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 13850-16-3
-
Appearance Solid
-
Molecular Weight 488.70
-
Formula C30H48O5
-
Color White to off-white
-
SMILES
OC([C@]12[C@]([C@](O)([C@H](C)CC2)C)([H])C3=CC[C@@]([C@@]4([C@@](C(C)([C@@H](O)[C@H](O)C4)C)([H])CC5)C)([H])[C@]5(C)[C@]3(C)CC1)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Food Funct
Protective effects of a herbal combination (Dimocarpus longan and Orthosiphon stamineus) on metabolic-associated fatty liver disease via the ERα-PI3K-AKT pathway. [Abstract]2026 Feb 23. PMID: 41729581 -
Chem Biol Drug Des
Network Pharmacology-Based Analysis and In Vitro Experiments Validation Reveal Tormentic Acid Induces Apoptosis via PI3K/AKT/HSP90 Pathway in HepG2 Cells. [Abstract]2026 Jan;107(1):e70239. PMID: 41542898
Solvent & Solubility
DMSO : 50 mg/mL (102.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. An HJ, et al. Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-α expression through inactivation of the nuclear factor-κb pathway in RAW 264.7 macrophages. Int Immunopharmacol. 2011 Apr;11(4):504-10. [Content Brief]
[2]. Wu JB, et al. Tormentic acid, a major component of suspension cells of Eriobotrya japonica, suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation. J Agric Food Chem. 2014 Nov 5;62(44):10717-26. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0462 mL | 10.2312 mL | 20.4625 mL | 51.1561 mL |
| 5 mM | 0.4092 mL | 2.0462 mL | 4.0925 mL | 10.2312 mL | |
| 10 mM | 0.2046 mL | 1.0231 mL | 2.0462 mL | 5.1156 mL | |
| 15 mM | 0.1364 mL | 0.6821 mL | 1.3642 mL | 3.4104 mL | |
| 20 mM | 0.1023 mL | 0.5116 mL | 1.0231 mL | 2.5578 mL | |
| 25 mM | 0.0818 mL | 0.4092 mL | 0.8185 mL | 2.0462 mL | |
| 30 mM | 0.0682 mL | 0.3410 mL | 0.6821 mL | 1.7052 mL | |
| 40 mM | 0.0512 mL | 0.2558 mL | 0.5116 mL | 1.2789 mL | |
| 50 mM | 0.0409 mL | 0.2046 mL | 0.4092 mL | 1.0231 mL | |
| 60 mM | 0.0341 mL | 0.1705 mL | 0.3410 mL | 0.8526 mL | |
| 80 mM | 0.0256 mL | 0.1279 mL | 0.2558 mL | 0.6395 mL | |
| 100 mM | 0.0205 mL | 0.1023 mL | 0.2046 mL | 0.5116 mL |